… transplant recipients who received valganciclovir prophylaxis for 100 days [11]. In stem
cell transplant recipients, preemptive therapy … for solid organ transplant recipients. Meta-analyses …

… At present, preemptive therapy for transplant recipients may be based on results of the
antigenemia test or quantitative PCR, depending on access to the tests. The novel application of …

… recipient. In this study, serial blood samples from 689 kidney or liver transplant recipients
were … CMV was managed using preemptive antiviral therapy and no patient received antiviral …

… Preemptive therapy is effective compared with placebo or standard care, but additional …
preemptive therapy and prophylaxis to prevent CMV disease in solid organ transplant recipients. …

… In conclusion, ganciclovir resistance is common in lung transplant recipients, especially D +
/R − patients. The preemptive therapy directed at pp65 antigenemia used in this study was of …

… transplant recipients with seropositive donors, high rates of delayed-onset postprophylaxis
CMV disease occur. An alternate approach, preemptive therapy (initiation of antiviral therapy …

… mutations) was also more frequent in the preemptive group (16% vs. 3… In summary, preemptive
therapy in D+R− KTR with high … In conclusion, preemptive therapy is associated with high …

… In this study, we compared prophylaxis and preemptive therapy for the … /recipient-seronegative
(Dþ/RÀ) liver recipients. To this end, we selected a retrospective cohort of liver recipients (…

… of morbidity in renal transplant recipients. We report our preliminary evaluation of the efficacy
and security of preemptive therapy to manage renal transplant recipients with evidence of …

… In the present study, SOT recipients receiving valganciclovir preemptive therapy for CMV
infection frequently developed hematological toxicity, especially neutropenia. However, and …